Savara (NASDAQ:SVRA – Get Free Report) and Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares Savara and Enanta Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Savara | N/A | N/A | -$95.88 million | ($0.53) | -10.60 |
| Enanta Pharmaceuticals | $65.32 million | 6.85 | -$81.89 million | ($3.20) | -4.82 |
Risk & Volatility
Savara has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Profitability
This table compares Savara and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Savara | N/A | -86.60% | -65.44% |
| Enanta Pharmaceuticals | -106.80% | -78.58% | -23.18% |
Insider and Institutional Ownership
87.9% of Savara shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Savara and Enanta Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Savara | 1 | 1 | 6 | 1 | 2.78 |
| Enanta Pharmaceuticals | 1 | 0 | 6 | 0 | 2.71 |
Savara presently has a consensus price target of $8.86, suggesting a potential upside of 57.60%. Enanta Pharmaceuticals has a consensus price target of $20.33, suggesting a potential upside of 31.95%. Given Savara’s stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Enanta Pharmaceuticals.
Summary
Enanta Pharmaceuticals beats Savara on 8 of the 13 factors compared between the two stocks.
About Savara
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
